Universal Biosensors, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-11-17: Form 8-K; Period of report 2025-11-14; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2025-07-07: Form 8-K; Period of report 2025-06-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2025-05-12: Form 8-K; Period of report 2025-05-12; Description 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure; Details 5.07.
- 2025-04-01: Form 8-K; Period of report 2025-04-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-11-17 | 8-K | 2025-11-14 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On November 14, 2025, PricewaterhouseCoopers (“PwC”) resigned as the independent registered public accounting firm of Universal Biosensors, Inc. (the “Company”). | 8-k_pwcresignat.htm |
| 2025-07-07 | 8-K | 2025-06-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 30, 2025, Craig Coleman resigned as a member of the Board of Directors (the “Board”) of Universal Biosensors, Inc. (the “Company”). | ubi20250706_8k.htm |
| 2025-05-12 | 8-K | 2025-05-12 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on May 12, 2025. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on May 12, 2025. | ubi20250512_8k.htm |
| 2025-04-01 | 8-K | 2025-04-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On April 1, 2025 (the “Effective Date”), Universal Biosensors, Inc. (the “Company”) announced that John Sharman resigned from his position as Chief Executive Officer and Managing Director on the Board of Directors (the “Board”) of the Company, effective on the Effective Date. 7.01 On the Effective Date, the Company issued a press release announcing the resignation of Mr. Sharman and the appointment of Mr. Mullin as Chief Executive Officer and Managing Director. | ubi20250401_8k.htm |
| 2025-01-15 | 8-K | 2025-01-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 15, 2025, the board of directors (the “Board”) of Universal Biosensors, Inc. (the “Company”) increased the size of the Board from four to six members and appointed John Sharman, the Company’s Chief Executive Officer, and Peter Mullin, the Company’s Chief Financial Officer, to fill the newly created vacancy as Class II and Class I directors, respectively, effective immediately. | ubi20250114_8k.htm |
| 2025-01-07 | 8-K | 2024-12-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 31, 2024, Universal Biosensors, Inc. (the “Company”) announced that its board of directors (the “Board”) appointed Peter Mullin as Chief Financial Officer and Finance Director. | ubi20250106_8k.htm |
| 2024-05-30 | 8-K | 2024-05-30 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on May 30, 2024. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on May 30, 2024. | ubi20240530_8k.htm |
| 2024-04-11 | 8-K | 2024-04-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information relating to the issuance of CDIs, the Offer Options, and the Underwriter Options (collectively, the “Securities”) in connection with the Entitlement Offer disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. 5.03 On April 10, 2024, following stockholder approval at the Meeting (as defined below), the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company’s common stock from 300,000,000 shares to 750,000,000 shares. 5.07 On April 10, 2024, the Company held a special meeting of stockholders (the “Meeting”). 8.01 On April 11, 2024 (April 11, 2024 in Australia), the Company commenced the delivery to the stockholders of the Company a written notice with respect to the Entitlement Offer, as required by the ASX Listing Rules. | ubi20240411_8k.htm |
| 2024-03-29 | 8-K | 2024-03-25 | 3.02 Unregistered Sales of Equity Securities | 3.02 On March 25, 2024, Universal Biosensors, Inc. (the “Company”) issued 16,666,667 CHESS Depositary Interests over fully paid shares of common stock of the Company (“CDIs”) at A$0.15 per CDI in a placement offering (the “Placement”) to selected institutional investors (the “Placement Participants”) and received aggregate gross proceeds of approximately A$2.5 million in connection therewith. | ubi20240329_8k.htm |
| 2024-03-15 | 8-K | 2024-03-15 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 15, 2024, the board of directors of Universal Biosensors, Inc. (the “Company”) approved an amendment to and restated the amended and restated bylaws of the Company (as amended and restated, the “Amended and Restated Bylaws”) effective immediately to change the default voting standard for any matter brought before any meeting of stockholders (other than the election of directors) from the approval by an affirmative vote by the holders of majority of the shares present and entitled to vote at such meeting to the approval by a majority of the votes cast by the stockholders on the matter at such meeting. | ubi20240314_8k.htm |
| 2024-03-05 | 8-K | 2024-02-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ubi20240304_8k.htm |
| 2023-05-22 | 8-K | 2023-05-22 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on May 22, 2023. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on May 22, 2023. | ubi20230521_8k.htm |
| 2022-06-21 | 8-K | 2022-06-21 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 21, 2022. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on June 21, 2022. | ubi20220620_8k.htm |
| 2022-05-25 | 8-K | 2022-05-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc. (the “Company”) held its special meeting of stockholders on May 23, 2022. | ubi20220524_8k.htm |
| 2022-04-22 | 8-K | 2022-04-19 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 To the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02. 8.01 On April 19, 2022 (April 20, 2022 in Australia), the Company commenced the delivery to the stockholders of the Company a written notice with respect to the Entitlement Offer, as required by the Listing Rules of Australian Securities Exchange Ltd and the Corporations Act of Australia. | ubi20220421_8k.htm |
| 2022-03-07 | 8-K | 2022-03-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 7, 2022, the Board of Directors (the “Board”) of Universal Biosensors, Inc. (“UBI”) elected Graham McLean to fill a vacancy on the Board. | ubi20220303_8k.htm |
| 2021-09-17 | 8-K | 2021-08-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 5, 2021, the Board of Directors (the “Board”) of Universal Biosensors Inc. (the “Company”) approved the amendment and restatement of the Universal Biosensors Inc. CEO Option Plan, dated March 24, 2020 (the “Amended CEO Plan”). | ubi20210915_8k.htm |
| 2021-07-06 | 8-K | 2021-06-30 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 30, 2021. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on June 30, 2021. | ubi20210703_8k.htm |
| 2021-03-18 | 8-K | 2021-01-27 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into Force of a Material Definitive Agreement. 5.02 On February 28, 2021, the Company granted certain equity awards to each of Messrs. | ubi20210317b_8k.htm |
| 2021-03-17 | 8-K | 2021-03-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 17, 2021, Mr. Marshall Heinberg resigned from the Board of Directors of Universal Biosensors, Inc. (“UBI”). | ubi20210317_8k.htm |
| 2020-07-24 | 8-K | 2020-07-24 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on July 24, 2020. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on July 24, 2020. | d891810d8k.htm |
| 2020-05-26 | 8-K | 2020-05-25 | 7.01 Regulation FD Disclosure | 7.01 On May 25, 2020, Universal Biosensors, Inc. (the “Company”) filed a release with the Australian Securities Exchange (“ASX”). | d929793d8k.htm |
| 2019-09-23 | 8-K | 2019-09-18 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on September 23, 2019 announcing that UBI and Siemens executed the Definitive Agreements on September 18, 2019. | d801522d8k.htm |
| 2019-09-09 | 8-K | 2019-09-09 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.02 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on September 9, 2019 providing an update on the Company’s sales activity and cash position. 7.01 The information provided in Item 1.01 and Item 2.02 is incorporated by reference into this Item 7.01. 8.01 On September 9, 2019, the Company announced that the Board had approved an on-market buyback of up to 10% of UBI’s securities over the 12 months following October 14, 2019. | d714199d8k.htm |
| 2019-08-22 | 8-K | 2019-08-21 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on August 22, 2019 announcing that UBI and Siemens agreed to extend the term of the Term Sheet Agreement until September 30, 2019, effective as of August 21, 2019. | d768131d8k.htm |
| 2019-06-27 | 8-K | 2019-06-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On June 26, 2019, the Board appointed Mr. Salesh Balak as interim Principal Executive Officer commencing on July 15, 2019 in Melbourne, Australia. 7.01 On June 26, 2019, the Company filed a release with the Australian Securities Exchange (“ASX”) announcing this interim Principal Executive Officer appointment. | d771323d8k.htm |
| 2019-06-26 | 8-K | 2019-06-25 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 25, 2019. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on June 25, 2019. | d719972d8k.htm |
| 2019-05-30 | 8-K | 2019-05-29 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on May 30, 2019 announcing that UBI and Siemens agreed to extend the term of the Term Sheet Agreement by 90 days, effective as of May 29, 2019. | d755147d8k.htm |
| 2019-03-08 | 8-K | 2019-03-08 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 2.02 Universal Biosensors, Inc. (the “Company”) filed a release with the Australian Securities Exchange (“First ASX Release”) on March 8, 2019, providing an update on its business activities and a review of its fiscal year ended December 31, 2018 results. 5.02 On March 8, 2019, Mr. Rick Legleiter resigned as Chief Executive Officer effective July 15, 2019. 7.01 The information provided in Item 2.02 is incorporated by reference into this Item 7.01. | d719310d8k.htm |
| 2019-02-11 | 8-K | 2019-02-08 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.03 Pursuant to the Term Sheet Agreement described above under Item 1.01, UBI has agreed not to make dividend payments or similar distributions during the Negotiation Period described in the Term Sheet Agreement. 7.01 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on February 11, 2019 announcing entry into the Term Sheet Agreement. | d699909d8k.htm |
| 2018-12-20 | 8-K | 2018-12-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 14, 2018, Dr. Adrian Oates resigned as Vice President Quality and Clinical of our wholly owned subsidiary, Universal Biosensors Pty Ltd. Dr. Oates’ final day with Universal Biosensors Pty Ltd is expected to be March 8, 2019. | d676512d8k.htm |
| 2018-11-20 | 8-K | 2018-11-20 | 7.01 Regulation FD Disclosure | 7.01 On November 20, 2018, Universal Biosensors, Inc. (the “Company”) gave notice to Athyrium Opportunities Fund (A) LP (“Athyrium A”) to prepay the outstanding loan of US$15,000,000 on November 26, 2018. | d656978d8k.htm |
| 2018-09-28 | 8-K | 2018-09-26 | 7.01 Regulation FD Disclosure | 7.01 On September 25, 2018, Universal Biosensors, Inc. (“UBI”) and its wholly owned subsidiary, Universal Biosensors Pty Ltd (“UBS”) received notice from Cilag GmbH International acting through its LifeScan division (“LifeScan”) of LifeScan’s exercise of its right to convert (or “buyout”) its obligation to pay quarterly service fees to UBS pursuant to the terms of the Master Services and Supply Agreement between UBI, UBS and LifeScan dated October 29, 2007, as amended and restated. | d619438d8k.htm |
| 2018-07-11 | 8-K | 2018-06-25 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 25, 2018. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on June 25, 2018. | d425184d8k.htm |
| 2018-04-24 | 8-K | 2018-04-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 23, 2018, Dr. Alastair Hodges gave notice of his resignation as Chief Scientist of our wholly owned subsidiary, Universal Biosensors Pty Ltd, which will take effect on July 13, 2018. | d566367d8k.htm |
| 2018-04-13 | 8-K | 2018-04-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On 12 April 2018, Mr. Garry Chambers resigned as Vice President, Technology Development of Universal Biosensors Inc. and its wholly owned subsidiary Universal Biosensors Pty Ltd. The Company thanks Mr. Chambers for his service. | d561917d8k.htm |
| 2018-01-03 | 8-K | 2017-12-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 On December 29, 2017, Universal Biosensors, Inc. (“UBI”) and its wholly owned subsidiary, Universal Biosensors Pty Ltd (“Borrower”) entered into Amendment No. 2 and Consent to the Credit Agreement, dated December 19, 2013 (as amended by Amendment No. 1, dated January 30, 2015, the “Credit Agreement”), with Athyrium Opportunities Fund (A) LP (“Athyrium A”), as administrative agent (the “Administrative Agent”) and as a lender, and Athyrium Opportunities Fund (B) LP (“Athyrium B”) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the “Lenders”) (the “Amendment”). 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. 7.01 UBI issued a press release on January 2, 2018 announcing the Amendment. | d451582d8k.htm |
| 2017-08-07 | 8-K | 2017-08-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 7, 2017, the Board appointed Mr. Rick Legleiter as full-time Chief Executive Officer commencing on October 1, 2017 in Melbourne, Australia. | d402646d8k.htm |
| 2017-06-23 | 8-K | 2017-06-22 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 22, 2017. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on June 22, 2017. | d408219d8k.htm |
| 2016-06-30 | 8-K | 2016-06-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 30, 2016, the Board of Directors (the “Board”) of Universal Biosensors, Inc. (the “Company”) elected Mr. Craig Coleman to fill a vacancy on the Board. | d210606d8k.htm |
| 2016-06-23 | 8-K | 2016-06-21 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 21, 2016. 7.01 The Company is furnishing presentation materials that the Company used during its annual meeting of stockholders on June 21, 2016. | d217090d8k.htm |
| 2016-03-09 | 8-K | 2016-03-09 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 7.01 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on March 9, 2016 announcing the amendment to the above agreements by the Prepayment Letter. | d156524d8k.htm |
| 2016-03-03 | 8-K | 2016-03-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On March 2, 2016, the Board of Directors (“Board”) of Universal Biosensors, Inc. (“Company”) appointed Mr. David Hoey to the Board. 7.01 The Company filed a release with the Australian Securities Exchange (“ASX Release”) on March 2, 2016 announcing the appointment of Mr. Hoey. | d153747d8k.htm |
| 2016-02-19 | 8-K | 2016-02-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 18, 2016, Mr. Paul Wright and Universal Biosensors Pty Ltd (“UBS”) entered into a separation agreement (“Separation Agreement”) under which the parties mutually agreed to the terms of Mr. Wright’s retirement as Chief Executive Officer and resignation from the Board of Directors (“Board”) of Universal Biosensors, Inc. (“Company”) and UBS, effective from March 10, 2016. | d145408d8k.htm |
| 2016-02-19 | 8-K | 2016-02-17 | 2.02 Results of Operations and Financial Condition | 2.02 On February 17, 2016, Universal Biosensors, Inc. (the “Company”) filed a report with the Australian Securities Exchange (the “ASX Report”) in which the Company announced its financial results for its fourth quarter and fiscal year ended December 31, 2015. | d145224d8k.htm |
| 2015-08-14 | 8-K | 2015-08-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 11, 2015, Mr. Chris Smith informed Universal Biosensors, Inc. (the “Company”) of his resignation from the Board of Directors (“Board”), including his role as member of the Remuneration and Nomination Committee, with effect from August 30, 2015. | d45538d8k.htm |
| 2015-07-13 | 8-K | 2015-07-09 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on July 9, 2015. | d15844d8k.htm |
| 2015-03-18 | 8-K | 2015-03-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 12, 2015, Mr. Andrew Jane informed Universal Biosensors, Inc. (the “Company”) of his resignation from the Board of Directors (“Board”), including his roles as Chair of the Remuneration and Nomination Committee and member of the Audit and Compliance Committee. | d894642d8k.htm |
| 2015-02-02 | 8-K | 2015-01-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. 7.01 UBI issued a press release on February 2, 2015 announcing the Amendment. | d864176d8k.htm |
| 2014-06-17 | 8-K | 2014-06-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc. (the “Company”) held its annual meeting of stockholders on June 12, 2014. | d745276d8k.htm |
| 2014-04-16 | 8-K | 2014-03-24 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 24, 2014, Universal Biosensors Pty Ltd (“UBS”) and Bowmayne Pty Ltd (“Lessor”) entered into a Deed of Extension and Variation of Lease (“Deed”) in relation to the extension and variation of the lease of its principal office at 1 Corporate Avenue, Rowville Victoria 3178 in Australia (“Premises”). | d712178d8k.htm |
| 2013-12-20 | 8-K | 2013-12-19 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosures set forth under Item 1.01 of this current report on Form 8-K are incorporated by reference herein. 3.02 The disclosures set forth under Item 1.01 of this current report on Form 8-K relating to the Warrant Agreements are incorporated by reference herein. | d647888d8k.htm |
| 2013-09-03 | 8-K | 2013-08-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 27, 2013, Dr. Elizabeth (Jane) Wilson informed Universal Biosensors, Inc. (the “Company”) of her resignation from the Board of Directors (“Board”), including her role as Chair of the Audit Committee. | d592479d8k.htm |
| 2013-05-20 | 8-K | 2013-05-16 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc (the “Company”) held its annual meeting of stockholders on May 16, 2013. | d542880d8k.htm |
| 2013-02-05 | 8-K | 2013-02-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 30, 2013, Dr. Colin Adam informed Universal Biosensors, Inc. (the “Company”) that he will not stand for re-election to the Board of Directors when his term expires at the upcoming 2013 annual meeting of stockholders. | d479101d8k.htm |
| 2012-11-28 | 8-K | 2012-11-23 | 3.02 Unregistered Sales of Equity Securities | 3.02 On November 23, 2012, Universal Biosensors, Inc., a Delaware corporation (the “Company”), agreed to issue 13,334,000 shares of common stock to certain institutional investors primarily in Australia at an issue price of A$0.90 per share (the “Placement”) raising approximately A$12 million (before expenses). | d445722d8k.htm |
| 2012-09-21 | 8-K | 2012-09-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 As previously disclosed by the Company, our wholly-owned operating subsidiary, Universal Biosensors Pty Ltd (“UBS”), and Siemens Healthcare Diagnostics Inc. (“Siemens”) are parties to a Collaboration Agreement dated September 9, 2011 (the “Collaboration Agreement”), pursuant to which the parties are collaborating in the development of three coagulation-related test strip products (the “Products”), and associated readers for the Products (the “Readers”) for commercialization by Siemens in the hospital point-of-care and ambulatory care coagulation markets. | d414724d8k.htm |
| 2012-05-14 | 8-K | 2012-05-10 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc (the “Company”) held its annual meeting of stockholders on May 10, 2012. | d351902d8k.htm |
| 2011-10-11 | 8-K | 2011-10-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 The following is a brief summary of the Novation and First Amendment to the Amended and Restated Master Services and Supply Agreement, the Statement of Work under the terms of the Amended and Restated Development and Research Agreement and the Second Amendment to the Amended and Restated Master Services and Supply Agreement. | w84331e8vk.htm |
| 2011-09-19 | 8-K/A | 2011-09-16 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 13, 2011, the Company reported in the Original Filing that stockholders holding at least a majority of the shares of its outstanding stock entitled to vote at the Company’s annual meeting of stockholders for 2011 had voted to recommend annual stockholder advisory votes on senior executive compensation. | w84373e8vkza.htm |
| 2011-09-09 | 8-K | 2011-09-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 On September 9, 2011 our wholly owned operating subsidiary Universal Biosensors Pty Ltd (“UBS”) and Siemens Healthcare Diagnostics, Inc. (“Siemens”) entered into a collaboration agreement which contains the terms pursuant to which UBS will develop coagulation related products for the hospital point-of-care and ambulatory care coagulation markets and Siemens will commercialize the developed products (“Agreement”). | w84213e8vk.htm |
| 2011-08-30 | 8-K | 2011-08-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 The following is a brief summary of the Amended and Restated License Agreement with LifeScan, Inc. and Amended and Restated Development and Research Agreement with Cilag GMBH International, complete copies of which are filed as exhibits hereto. | w84097e8vk.htm |
| 2011-05-13 | 8-K | 2011-05-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc (the “Company”) held its annual meeting of stockholders on May 12, 2011. | w82843e8vk.htm |
| 2011-02-25 | 8-K | 2011-02-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) On February 24, 2011, Universal Biosensors, Inc. (the “Company”) announced that Paul Wright has been appointed as Chief Executive Officer of the Company effective on March 1, 2011 (the “Effective Date”). | w81779e8vk.htm |
| 2010-12-22 | 8-K/A | 2010-12-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with Mr. Denver’s appointment to serve as the interim Chief Executive Officer of UBP and the Company, UBP (the entity that employs all of the employees of the Company and UBP) entered into a letter agreement with Mr. Denver on December 22, 2010 that is to be effective as of September 9, 2010 (the “Denver Employment Agreement”). | w80954e8vkza.htm |
| 2010-09-15 | 8-K | 2010-09-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On September 9, 2010, Mr. Mark Morrisson retired as a member of the Board of Directors and as the Chief Executive Officer of Universal Biosensors, Inc. (the “Company”) and as a member of the Board of Directors of the Company’s wholly owned operating subsidiary, Universal Biosensors Pty Ltd (“UBP”). | w79817e8vk.htm |
| 2010-05-14 | 8-K | 2010-05-13 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Universal Biosensors, Inc (the “Company”) held its annual meeting of stockholders on May 13, 2010. | w78555e8vk.htm |
| 2010-01-14 | 8-K | 2010-01-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 11, 2010, Charles Kiefel resigned as a director of Universal Biosensors, Inc. (the “Company”) effective immediately. | w76998e8vk.htm |
| 2009-05-18 | 8-K | 2009-05-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 On October 29, 2007, Universal Biosensors, Inc. (“UBI”) and its wholly owned operating subsidiary Universal Biosensors Pty Ltd (“UBS”) entered into a master services and supply agreement with LifeScan, Inc. (“LifeScan”) pursuant to which UBS agreed to provide certain services in the field of blood glucose monitoring to LifeScan and act as a non-exclusive manufacturer of certain blood glucose test strips to LifeScan. | w74153e8vk.htm |
| 2007-11-16 | 8-K | 2007-11-09 | 1.01 Entry into a Material Definitive Agreement | w42875e8vk.htm | |
| 2007-11-02 | 8-K | 2007-10-29 | 1.01 Entry into a Material Definitive Agreement | w41769e8vk.htm | |
| 2007-10-30 | 8-K | 2007-10-30 | 8.01 Other Events | w41584e8vk.htm |